カテゴリ： MarketLine, ドイツ, 企業調査

Lanxess AG：企業の戦略・SWOT・財務情報

◆英語タイトル：Lanxess AG - Strategy, SWOT and Corporate Finance Report
◆商品コード：DATA904C3715
◆発行会社（調査会社）：MarketLine
◆発行日：2018年8月
◆ページ数：50
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：化学
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD175 ⇒換算￥25,900見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD350 ⇒換算￥51,800見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD525 ⇒換算￥77,700見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※MarketLine社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Lanxess AG – Strategy, SWOT and Corporate Finance Report
Summary

Lanxess AG – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Lanxess AG (Lanxess or ‘the company’) is a leading specialty chemicals company. The company’s product portfolio comprises chlorobenzenes, chlorotoluenes, cresols, nitrotoluenes and their derivatives, amines, benzyl products, hydrofluoric acid, maleic anhydride, hydrazine hydrate, trimethylol propane and hexandiol. It also supplies synthetic rubbers through ARLANXEO, a joint venture with Saudi Aramco. The company’s products find applications in the areas of agrochemicals, automotive, construction, aromas and flavors, pharmaceuticals, tire chemicals, electrical, electronics and medical equipment, leather processing and water treatment, among others. Lanxess operates across Europe, the Middle East and Africa (EMEA), North America, Latin America and Asia-Pacific. Lanxess is headquartered in Cologne, North Rhine-Westphalia, Germany.

Scope

- Detailed information on Lanxess AG required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Lanxess AG in the form of a SWOT analysis
- An in-depth view of the business model of Lanxess AG including a breakdown and examination of key business segments
- Intelligence on Lanxess AG’s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Lanxess AG, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of Lanxess AG and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Lanxess AG as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on Lanxess AG’s business structure, strategy and prospects.

【レポートの目次】

Table of Contents
Company Snapshot 2
Table of Contents 5
Lanxess AG: Company Overview 9
Lanxess AG: Overview and Key Facts 9
Lanxess AG: Overview 9
Lanxess AG: Key Facts 9
Lanxess AG: Key Employees 11
Lanxess AG: Key Employee Biographies 12
Lanxess AG: Major Products and Services 18
Lanxess AG: Company History 19
Lanxess AG: Management Statement 23
Lanxess AG: Key Competitors 24
Lanxess AG: Company Analysis 25
Lanxess AG: Business Description 25
Lanxess AG: SWOT Analysis 27
Lanxess AG: SWOT Overview 27
Lanxess AG: Strengths 27
Lanxess AG: Weaknesses 28
Lanxess AG: Opportunities 28
Lanxess AG: Threats 29
Lanxess AG: Corporate Financial Deals Activity 31
Lanxess AG: Financial Deals Overview 31
Lanxess AG: Targets and Partners 32
Lanxess AG: Top Deals 2014 – 2018YTD* 33
Lanxess AG: Advisors 34
Lanxess AG: Top Legal Advisors 34
Lanxess AG: Mergers and Acquisitions 35
Lanxess AG: Capital Raising 36
Lanxess AG: Partnership 37
Lanxess AG: Divestments 38
Lanxess AG: Private Equity and Ownership 39
Lanxess AG: Recent Developments 40
Lanxess AG: News and Events Summary 40
Lanxess AG: Business Expansion 43
Lanxess AG: Corporate Governance 44
Lanxess AG: Financial Deals 45
Lanxess AG: Strategy and Operations 45
Appendix 48
Contact Us 48
Methodology 48
About MarketLine 49

List of Tables
Table 1: Lanxess AG: Key Facts
Table 2: Lanxess AG: Key Employees
Table 3: Lanxess AG: Key Competitors
Table 4: Lanxess AG: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Table 5: Lanxess AG: M&A Average Deal Size - Value (US$m)
Table 6: Lanxess AG: Targets and Partners
Table 7: Lanxess AG: Top Deals 2014 - 2018YTD*
Table 8: Lanxess AG: Legal Advisor Ranking by Value (US$m)
Table 9: Lanxess AG: M&A Volume and Value Trend (2014 - YTD*2018)
Table 10: Lanxess AG: M&A Activity by Geography (2014 - YTD*2018)
Table 11: Lanxess AG: Capital Raising Volume and Value Trend (2014 - YTD*2018)
Table 12: Lanxess AG: Capital Raising by Deal Type (2014 - YTD*2018)
Table 13: Lanxess AG: Partnership Volume and Value Trend (2014 - YTD*2018)
Table 14: Lanxess AG: Partnership Trend by Deal Type (2014 - YTD*2018)
Table 15: Lanxess AG: Divestments Volume and Value Trend (2014 - YTD*2018)
Table 16: Lanxess AG: Divestments by Geography (2014 - YTD*2018)
Table 17: Lanxess AG: Private Equity and Ownership Volume and Value Trend (2014 - YTD*2018)
Table 18: Lanxess AG: Private Equity and Ownership Volume by Deal Type (2014 - YTD*2018)
Table 19: Lanxess AG: News and Events Summary
Table 20: Lanxess AG: Business Expansion
Table 21: Lanxess AG: Corporate Governance
Table 22: Lanxess AG: Financial Deals
Table 23: Lanxess AG: Strategy and Operations

List of Figures
Figure 1: Lanxess AG: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Figure 2: Lanxess AG: M&A Average Deal Size - Value (US$m)
Figure 3: Lanxess AG: M&A Volume and Value Trend (2014 - YTD*2018)
Figure 4: Lanxess AG: M&A Activity by Geography (2014 - YTD*2018)
Figure 5: Lanxess AG: Capital Raising Volume and Value Trend (2014 - YTD*2018)
Figure 6: Lanxess AG: Capital Raising by Deal Type (2014 - YTD*2018)
Figure 7: Lanxess AG: Partnership Volume and Value Trend (2014 - YTD*2018)
Figure 8: Lanxess AG: Partnership Trend by Deal Type (2014 - YTD*2018)
Figure 9: Lanxess AG: Divestments Volume and Value Trend (2014 - YTD*2018)
Figure 10: Lanxess AG: Divestments by Geography (2014 - YTD*2018)
Figure 11: Lanxess AG: Private Equity and Ownership Volume and Value Trend (2014 - YTD*2018)
Figure 12: Lanxess AG: Private Equity and Ownership Volume by Deal Type (2014 - YTD*2018)

★海外企業調査レポート[Lanxess AG：企業の戦略・SWOT・財務情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Softchoice Corporation：企業の戦略的SWOT分析
    Softchoice Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Neuro Kinetics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Neuro Kinetics Inc (Neuro Kinetics) is a medical device manufacturing company that offers eye tracking technology and non-invasive neuro-otologic diagnostic testing solutions. The company’s products include VNG diagnostic systems, vestibular and neuro-otologic testing systems, software packa …
  • Pennon Group Plc (PNN)：企業の財務・戦略的SWOT分析
    Pennon Group Plc (PNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Concordia International Corp (CXR)-製薬・医療分野：企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • Becton Dickinson and Co (BDX)-製薬・医療分野：企業M&A・提携分析
    Summary Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instrument. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management …
  • Curie Institute：製薬・医療：M&Aディール及び事業提携情報
    Summary Curie Institute is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biolo …
  • Bellway Plc (BWY)：企業の財務・戦略的SWOT分析
    Bellway Plc (BWY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Liebherr-International AG：企業の戦略・SWOT・財務分析
    Liebherr-International AG - Strategy, SWOT and Corporate Finance Report Summary Liebherr-International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Nintendo Co Ltd (7974)：企業の財務・戦略的SWOT分析
    Nintendo Co Ltd (7974) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Q BioMed Inc (QBIO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Q BioMed Inc (Q BioMed), formerly ISMO Tech Solutions Inc, is a biomedical acceleration and development company. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It develops Man-01, a pre-clinical lead c …
  • Tragara Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activ …
  • Michael Kors Holdings Ltd：企業の戦略・SWOT・財務情報
    Michael Kors Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Michael Kors Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SomaLogic Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …
  • Takuma Co Ltd (6013)：企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Elecnor SA (ENO)：企業の財務・戦略的SWOT分析
    Elecnor SA (ENO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • The Boeing Co (BA)：企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Ryosan Company, Ltd
    Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Buckeye Partners, L.P.：企業の戦略・SWOT・財務情報
    Buckeye Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Buckeye Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Empresas Copec S.A.：企業の戦略・SWOT・財務分析
    Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report Summary Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Canadian Cancer Trials Group：製薬・医療：M&Aディール及び事業提携情報
    Summary Canadian Cancer Trials Group (CCTG), is a subsidiary of Cancer Research Institute at Queen's University, is a contract research organization that conducts clinical trials. The company conducts trials for the development of new drugs and therapies for the treatment of various diseases. It pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆